



Hemerion to revolutionize solid tumors standard of care

THE PROBLEM

The losing battle against remaining cancer cells after surgery.

Solid tumors are primarily treated with surgery as the initial therapy. While this approach is effective, it is far from sufficient. No surgery can remove all cancer cells.

The remaining cells continue to proliferate, causing recurrences and reducing patients' life expectancy.

To eradicate these cells, medicine employs radiotherapy and chemotherapy. These treatments are lengthy, arduous, and costly. They have limited effectiveness, destroying both cancerous and healthy cells. They negatively impact patients' quality of life.

THE SOLUTION

A 30-minute single procedure to selectively destroy cancer cells, in the operating room, without affecting healthy cells.

Hemerion's technology is used intraoperatively during resection of solid tumors. It combines a **proprietary photosensitizing molecule**, Pentalafen®, and an **advanced light activation** platform, Heliance®.

- Pentalafen® is an oral drug. When administered to the patient before surgery, it accumulates in cancer cells **only**.
- The Heliance® illumination platform emits a very specific light that activates Pentalafen® **only** in cancer cells, destroying them.

The remaining cancer cells are selectively destroyed in a single 30-minute procedure performed in the operating room, just after the tumor removal, using an easy-to-use platform.



THE PERFORMANCE

Spectacular and robust clinical results in the treatment of brain cancer



The Hemerion technology is already recognized as a highly promising therapy in the treatment of glioblastoma, the most widespread and aggressive brain cancer.

Treated by surgery, radiotherapy and chemotherapy, this cancer offers no hope to patients, with a median survival of **only 15 months from diagnosis**. Hemerion's combined therapy for glioblastoma has undergone clinical trials in both Europe and the United States. These trials included 25 patients treated with Hemerion and some of whom had a long-term follow-up. 40% of these patients were still alive 5 years after the operation, compared to only 6% observed for conventional treatment: a major leap in therapy effectiveness.

2
clinical studies achieved

6 x increase
in 5-year survival rates
(40% vs. 6%)

Long term follow-up of patients with newly diagnosed glioblastoma treated by intraoperative photodynamic therapy: an update from the INDYGO trial (NCT03048240). J Neurooncol. 2024

THE MARKET OPPORTUNITY

1 Glioblastoma: a rapidly accessible and profitable market

Safe, effective, fast and easy to implement, Hemerion combination therapy has all the assets needed to rapidly become the standard of care for glioblastoma in the United States and Europe with a very high probability of reimbursement by public and private payers.

Nearly
30 000
eligible
patients
per year

A total potential
market of
€900
million

Revenue of
€100
million
achieved by 2032

2 Redefining the role of radiotherapy in solid tumor treatment: a blockbuster market potential

Performed in a single 30-minute procedure with no risk to healthy tissue, Hemerion combined therapy directly challenges the use of radiation therapy - traditionally administered over six weeks. It's a real game-changer for the oncology market: better therapeutic results, shorter treatment times with no side effects, and a much better cost/benefit ratio.

Hemerion combined therapy could take a significant market share in the oncology market, gradually redefining how solid tumor radiotherapy is delivered to patients.



> 1 MILLION

Solid tumor patients
receive post-surgical
radiotherapy annually
across the US and EU

A scalable oncological
market for Hemerion

ECIS - European Cancer Information System / CDC - American Cancer Society - European Society for Radiotherapy and Oncology (ESTRO) - Mol Oncol. 2020 May 1;14(7):1461-1469

BUSINESS MODEL

Diversified & Recurring Revenue Model

- High-margin recurring revenue from single-use kits (per procedure)
- Initial Heliance® platform installation via flexible placement models (sales / leasing / rental)
- Long-term customer lock-in through service contracts

High profitability

- High perceived medical value ensuring strong payer coverage
- Scalable and cost-effective manufacturing



KEY STRENGTHS

- A safe, efficient, easy to use, ready to market disruptive therapy
- Proprietary, patented technology with the potential to make a name for itself in the treatment of a wide range of solid tumors
- Advanced clinical development in the US and the EU
- Highly effective regulatory strategy: ISO 13485 certification / Orphan Drug Designation in the EU and the US / Fast track Designation from the FDA / Drug and Device approved for clinical investigation by the EMA

INVESTOR RELATIONS



**Maximilien Vermandel, PhD, Physicist
Chief Executive Officer**

Founded Hemerion in 2020, after more than 20 years' experience in medical research management.



**Michel Andraud, HEC Business School /
Chief Financial Officer**

Extensive experience in the financial management of innovative healthcare companies.


FINANCING REQUIREMENTS

What we need to achieve success

Since its creation, Hemerion has raised €14 million: enough to guarantee the safety and feasibility of its combination therapy in France and the USA.

Hemerion needs to finance a pivotal phase to launch its first indication in glioblastoma in 2030: €40 million.

40 M€ TO ENTER OUR FIRST MARKET



STRATEGIC EXIT

What's in it for you

Hemerion offers a de-risked, first-in-class therapeutic platform with an accessible entry market and a blockbuster potential, addressing critical unmet medical needs in the surgical oncology market.

Hemerion aims at a potential acquisition or a licensing-out by major device or pharma players in 2029-2030, following our next key value inflection point: FDA and EMA approval for the glioblastoma indication.